Literature DB >> 35287524

Mortality of COVID-19 is associated with comorbidity in patients with chronic obstructive pulmonary disease.

Niklas Andreen1,2, Lars-Magnus Andersson1,2, Nicklas Sundell1,2, Lars Gustavsson1,2, Johan Westin1,2.   

Abstract

BACKGROUND: The aim of this study was to compare the outcome of coronavirus disease 2019 (COVID-19) in hospitalised patients with chronic obstructive pulmonary disease (COPD) with the outcome in matched COVID-19 patients without COPD.
METHODS: Sixty-three COPD patients hospitalised for acute COVID-19 from March through August 2020 were retrospectively identified and 63 hospitalised COVID-19 patients without COPD were selected and matched for age, gender and month of hospital admission.
RESULTS: COPD patients had a higher rate of comorbidities, especially cardiovascular disease, and a trend towards a higher 30-day mortality than control patients (35% vs. 22%). In the COPD group, high Charlson comorbidity index (p = 0.03) and previous cerebrovascular disease (p = 0.04) were associated with 30-day mortality in univariate analysis. Inhaled corticosteroids maintenance therapy was not associated with lower mortality.
CONCLUSION: COPD patients hospitalised for acute COVID-19 disease had significantly more comorbidities and a high risk of severe outcome and death within 30 days. Comorbidity, especially cardiovascular diseases, was associated with mortality among COPD patients.

Entities:  

Keywords:  COPD; COVID-19; Coronavirus infection; disease severity; inhaled corticosteroids; mortality

Mesh:

Year:  2022        PMID: 35287524     DOI: 10.1080/23744235.2022.2050422

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  1 in total

1.  Impact of the COVID-19 Pandemic on the Use and Outcomes of Cardiac Procedures in COPD Patients.

Authors:  Javier de Miguel-Diez; Rodrigo Jimenez-Garcia; Jose M de Miguel-Yanes; Valentin Hernández-Barrera; David Carabantes-Alarcon; Jose J Zamorano-Leon; Concepción Noriega; Ana Lopez-de-Andres
Journal:  J Clin Med       Date:  2022-07-05       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.